000289122 001__ 289122
000289122 005__ 20250825122416.0
000289122 0247_ $$2doi$$a10.1016/j.critrevonc.2024.104331
000289122 0247_ $$2pmid$$apmid:38521284
000289122 0247_ $$2ISSN$$a0737-9587
000289122 0247_ $$2ISSN$$a1040-8428
000289122 0247_ $$2ISSN$$a1879-0461
000289122 0247_ $$2altmetric$$aaltmetric:161149955
000289122 037__ $$aDKFZ-2024-00589
000289122 041__ $$aEnglish
000289122 082__ $$a610
000289122 1001_ $$aHelderman, Noah C$$b0
000289122 245__ $$aEmerge of colorectal cancer in Lynch syndrome despite colonoscopy surveillance: A challenge of hide and seek.
000289122 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2024
000289122 3367_ $$2DRIVER$$aarticle
000289122 3367_ $$2DataCite$$aOutput Types/Journal article
000289122 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712309409_10719$$xReview Article
000289122 3367_ $$2BibTeX$$aARTICLE
000289122 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289122 3367_ $$00$$2EndNote$$aJournal Article
000289122 520__ $$aEven with colonoscopy surveillance, Lynch syndromes (LS) carriers still develop colorectal cancer (CRC). The cumulative incidence of CRCs under colonoscopy surveillance varies depending on the affected mismatch repair (MMR) gene. However, the precise mechanisms driving these epidemiological patterns remain incompletely understood. In recent years, several potential mechanisms explaining the occurrence of CRCs during colonoscopy surveillance have been proposed in individuals with and without LS. These encompass biological factors like concealed/accelerated carcinogenesis through a bypassed adenoma stage and accelerated progression from adenomas. Alongside these, various colonoscopy-related factors may contribute to formation of CRCs under colonoscopy surveillance, like missed yet detectable (pre)cancerous lesions, detected yet incompletely removed (pre)cancerous lesions, and colonoscopy-induced carcinogenesis due to tumor cell reimplantation. In this comprehensive literature update, we reviewed these potential factors and evaluated their relevance to each MMR group in an attempt to raise further awareness and stimulate research regarding this conflicting phenomenon.
000289122 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289122 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289122 650_7 $$2Other$$aColonoscopy surveillance
000289122 650_7 $$2Other$$aColorectal cancer
000289122 650_7 $$2Other$$aIncident colorectal cancer
000289122 650_7 $$2Other$$aLynch syndrome
000289122 650_7 $$2Other$$aMismatch repair
000289122 650_7 $$2Other$$aPost-colonoscopy colorectal cancer
000289122 7001_ $$avan Leerdam, Monique E$$b1
000289122 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b2$$udkfz
000289122 7001_ $$0P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aAhadova, Aysel$$b3$$udkfz
000289122 7001_ $$aNielsen, Maartje$$b4
000289122 773__ $$0PERI:(DE-600)2025731-4$$a10.1016/j.critrevonc.2024.104331$$gVol. 197, p. 104331 -$$p104331$$tCritical reviews in oncology, hematology$$v197$$x0737-9587$$y2024
000289122 8564_ $$uhttps://inrepo02.dkfz.de/record/289122/files/1-s2.0-S104084282400074X-main.pdf
000289122 8564_ $$uhttps://inrepo02.dkfz.de/record/289122/files/1-s2.0-S104084282400074X-main.pdf?subformat=pdfa$$xpdfa
000289122 909CO $$ooai:inrepo02.dkfz.de:289122$$pVDB
000289122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289122 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289122 9141_ $$y2024
000289122 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000289122 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCRIT REV ONCOL HEMAT : 2022$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000289122 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCRIT REV ONCOL HEMAT : 2022$$d2023-10-24
000289122 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x0
000289122 9201_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x1
000289122 980__ $$ajournal
000289122 980__ $$aVDB
000289122 980__ $$aI:(DE-He78)F210-20160331
000289122 980__ $$aI:(DE-He78)D470-20160331
000289122 980__ $$aUNRESTRICTED